Praxis Precision Medicines, Inc. (PRAX)

Market Cap	7.55B
Revenue (ttm)	7.46M
Net Income (ttm)	-273.04M
Shares Out	25.01M
EPS (ttm)	-12.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	593,595
Open	317.72
Previous Close	268.95
Day's Range	300.00 - 317.72
52-Week Range	26.70 - 317.72
Beta	2.97
Analysts	Strong Buy
Price Target	373.79 (+23.88%)
Earnings Date	Nov 5, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Analyst Summary

According to 14 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $373.79, which is an increase of 23.88% from the latest price.

Price Target

$373.79

(23.88% upside)

Analyst Consensus: Strong Buy